Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DSSN | ISIN: US98985Y1082 | Ticker-Symbol: ZA8
Tradegate
06.06.25 | 18:30
11,000 Euro
-0,90 % -0,100
1-Jahres-Chart
ZYMEWORKS INC Chart 1 Jahr
5-Tage-Chart
ZYMEWORKS INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,00011,20006.06.
11,00011,10006.06.

Aktuelle News zur ZYMEWORKS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ZYMEWORKS Aktie jetzt für 0€ handeln
DiStifel bekräftigt Kaufempfehlung für Zymeworks-Aktie nach ASCO-Tagung2
DiStifel reiterates buy rating for Zymeworks stock after ASCO meeting1
DiStifel-Analysten bekräftigen Kaufempfehlung für Zymeworks-Aktie nach ASCO-Update1
DiStifel analysts reaffirm Zymeworks stock buy rating after ASCO update2
MoH.C. Wainwright behält neutrales Rating für Zymeworks-Aktie bei1
MoH.C. Wainwright maintains neutral rating on Zymeworks stock1
MoZymeworks' zanidatamab gains approval in China for biliary tract cancer2
30.05.Zymeworks Inc. - 8-K, Current Report2
30.05.Zymeworks gets China's conditional approval for biliary tract cancer treatment1
30.05.Zymeworks Gets China's NMPA Approval For Zanidatamab1
30.05.Zymeworks Inc.: Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer254Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical...
► Artikel lesen
22.05.Zymeworks Inc.: Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences322Partner presentations reinforce ability of proprietary Azymetric platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii),...
► Artikel lesen
21.05.Zymeworks Inc.: Zymeworks Announces Participation in Upcoming Investor Conferences214VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics...
► Artikel lesen
20.05.Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities1
20.05.TD Cowen initiates Zymeworks stock with buy rating on potential1
19.05.Zymeworks Inc.: Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference401Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel...
► Artikel lesen
09.05.Zymeworks outlines robust pipeline advancements and financial resilience through 20272
08.05.Zymeworks May 2025 slides: Pipeline expansion amid modest revenue growth2
08.05.Zymeworks Inc. - 10-Q, Quarterly Report1
08.05.Zymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results122Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in...
► Artikel lesen
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1